
Satellos Phase 2 trial in boys with Duchenne will use MRI-measured fat fraction as primary efficacy endpoint
Satellos Bioscience, which received prior funding from CureDuchenne, has announced that after meeting with the FDA they have amended the primary endpoint in their Phase 2 BASECAMP trial to now […]








